logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Return

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)

delete2026-06-10
delete0
delete
OA
AI
B
Brandi N. Reeves
F
Firas El Chaer
L
Lynda Foltz
T
Tsewang Tashi
G
Ghaith Abu-Zeinah
A
Albert Qin
J
Jennifer Lucas
A
Anna B. Halpern
D
Dawn Maze
H
Hana Safah
C
Casey L. O’Connell
S
Swati Goel
L
Lindsay Rein
B
Bruno Fang
J
Joan How
S
Sunil Babu
Z
Zhuoyan Li
S
Sonia Cerquozzi
S
Stephen T. Oh
A
Anthony M. Hunter
DOI：10.1016/j.lana.2026.101529delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Ropeginterferon alfa-2b-njft (ropeg), a mono-PEGylated interferon-α, showed efficacy and safety in patients with hydroxyurea-intolerant/resistant essential thrombocythemia (ET) in the phase 3 SURPASS-ET largely conducted in Asia. Here we report the results from the EXCEED-ET study, which evaluated ropeg in both treatment-naïve and hydroxyurea pre-treated ET in North America.
Keywords:
Ropeginterferon alfa-2b-njft
Essential thrombocythemia
Treatment-naïve
Pre-treated
Northern American
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

T
The Lancet Regional Health - Americas
IF:
0
Papers:
174
Citations:
0

Organization

No organization information available